Current Treatment Options in Gastroenterology

, Volume 2, Issue 4, pp 289–293

Cystic fibrosis and pancreatic disease

  • Michele D. Bishop
  • Steven D. Freedman

Opinion statement

Cystic fibrosis encompasses a broad spectrum of disease activity. This is no longer considered only a childhood disease. In fact, many patients with the classic form of CF live well into adulthood, and many atypical forms of CF are now being studied. Based on gene mutations, patients may present in adulthood with single organ involvement such as chronic pancreatitis. Diagnosis and treatment of CF-related conditions are evolving areas of research and discovery. As new therapies emerge for cystic fibrosis, new therapies will also be available for related pancreatic disorders.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Collins FS: Cystic fibrosis: molecular biology and therapeutic implications. Science 1992, 256:774–779.PubMedCrossRefGoogle Scholar
  2. 2.
    Riordan JR, Rommens JM, Kerem B, et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066–1073.PubMedCrossRefGoogle Scholar
  3. 3.
    Website: Cystic fibrosis mutation data base. Cystic Fibrosis Genentic Analysis Consortium 1998.Google Scholar
  4. 4.
    Wilschanski M, Zielenski J, Markiewicz D, et al.: Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr 1995, 127:705–710. This paper describes the classification system for CFTR mutations.PubMedCrossRefGoogle Scholar
  5. 5.
    Kristidis P, Bozon D, Corey M, et al.: Genetic determin-ation of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992, 50:178–184.Google Scholar
  6. 6.
    PR: Exocrine pancreatic disease in CF-clinical insights. Ped Pulm 1997, 14:110–111.Google Scholar
  7. 7.
    Anguiano A, Oates RD, Amos JA, et al.: Congenital bilat-eral absence of the vas deferens-a primarily genital form of cystic fibrosis. JAMA 1992, 267:1794–1797.PubMedCrossRefGoogle Scholar
  8. 8.
    Jarvi K, Zielenski J, Wilschanski M, et al.: Cystic fibrosis transmembrane conductance regulator and obstructive azoospermia. Lancet 1995, 345:1578.PubMedCrossRefGoogle Scholar
  9. 9.
    Cohn JA, Friedman KJ, Noone PG, et al.: Relation between mutations of the cystic fibrosis gene and idio-pathic pancreatitis. N Engl J Med 1998, 339:653–658.PubMedCrossRefGoogle Scholar
  10. 10.
    Sharer N, Schwarz M, Malone G, et al.: Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998, 339:645–652. These were the first two published papers describing the association of CFTR gene mutations in chronic pancreatitis. Limited genetic screening found 37% and 13% of patients had mutations, respectively.PubMedCrossRefGoogle Scholar
  11. 11.
    Bishop MD, Freedman SD, Zielenski J, et al.: Does complete DNA analysis identify a higher percentage of cystic fibrosis gene mutations in patients with idiopathic recurrent acute and chronic pancreatitis? Gastroenterology 1999, 116:G4825. Patients with chronic or recurrent acute pancreatitis under-went more complete genetic analysis looking for >800 CFTR mutations and found a higher rate of mutations (62%).Google Scholar
  12. 12.
    Kopelman H, Durie P, Gaskin K, et al.: Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. N Engl J Med 1985, 312:329–334.PubMedCrossRefGoogle Scholar
  13. 13.
    Karanjia ND, Singh SM, Widdison AL, et al.: Pancreatic ductal and intestinal pressures in cats with chronic pancreatitis. Dig Dis Sci 1992, 37:268–273.PubMedCrossRefGoogle Scholar
  14. 14.
    Go VLW, Hoffman AF, Summerskill WHJ: Pancreozymin bioassay in man based on pancreatic enzyme secre-tion: potency of specific amino acids and other diges-tive products. J Clin Invest 1970, 49:1558–1564. This is a classic paper.PubMedGoogle Scholar
  15. 15.
    Liddle RA, Goldfine ID, William JA: Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibi-tor and alcohol. Gastroenterology 1984, 87:542–549.PubMedGoogle Scholar
  16. 16.
    Malagelada J-R, Go VLW, Summerskill WHJ: Different gastric, pancreatic and biliary responses to solid-liquid or homogenized meals. Dig Dis Sci 1979, 24:101–110. This is a classic paper.PubMedCrossRefGoogle Scholar
  17. 17.
    Uden S, Acheson DW, Reeves J, et al.: Antioxidants, enzyme induction and chronic pancreatitis: a reappraisal following studies in patients on anticonvulsants. Eur J Clin Nutr 1988, 42:561–569.PubMedGoogle Scholar
  18. 18.
    Rose P, Fraine E, Hunt LP, et al.: Dietary antioxidants and chronic pancreatitis. Hum Nutr Clin Nutr 1986, 40:151–164.PubMedGoogle Scholar
  19. 19.
    Braganza JM, Thomas A, Robinson A: Antioxidants to treat chronic pancreatitis in childhood? Case report and possible implications for pathogenesis. Int J Pancreatol 1988, 3:209–216.PubMedGoogle Scholar
  20. 20.
    Freedman SD: Peptamen: a novel therapy in patients with chronic pancreatitis. Gastroenterology 1997, 12:A267.Google Scholar
  21. 21.
    Ramsay BW, Farrell PM, Pencharz P, and the Concensus: Nutritional assessment and management in cystic fibro-sis: a consensus report. Am J Clin Nutr 1992, 55:109–116.Google Scholar
  22. 22.
    Pencharz PB, Durie PR: Nutritional Management of Cystic Fibrosis. Annu Rev Nutr 1993, 13:111–136. Dietary guidelines for patients with classic cystic fibrosis.PubMedCrossRefGoogle Scholar
  23. 23.
    Dowsett J: Nutrition in the Management of Cystic Fibrosis. Nutrition Reviews 1996, 54:31–33.PubMedCrossRefGoogle Scholar
  24. 24.
    Zeitlin PL: Novel pharmacologic therapies for cystic fibrosis. J Clin Invest 1999, 103:447–452. The spectrum of defects in CFTR is described by class of mutation, followed by a review of potential therapies and preliminary data.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Michele D. Bishop
    • 1
  • Steven D. Freedman
    • 1
  1. 1.Division of Gastroenterology, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBoston

Personalised recommendations